Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Ablexis, Tri-Institutional Therapeutics Discovery Institute deal

    Ablexis granted the institute non-exclusive rights to use the AlivaMab Mouse transgenic mouse technology to discover human antibodies. Ablexis will receive an eight-figure payment. Ablexis declined to disclose financial…

    Published on 1/23/2017
  • Amunix, Biogen deal

    Amunix said Biogen exercised its option under a 2011 deal for exclusive, worldwide development and commercialization rights to an undisclosed recombinant Factor IX candidate that uses Amunixs recombinant XTEN technology…

    Published on 1/23/2017
  • APT Therapeutics, AZ deal

    The companies partnered to develop APT's APT102. APT will receive an upfront payment and is eligible for development milestones. AstraZeneca, which has an option to acquire the product, will fund trials of APT102 to …

    Published on 1/23/2017
  • Chroma, Macrophage deal

    Chroma granted Macrophage worldwide rights to Chroma's Esterase Sensitive Motif (ESM) technology plus therapeutic assets in discovery, including a phosphoinositide 3-kinase (PI3K) inhibitor. ESM delivers small molecules…

    Published on 1/23/2017
  • CoLucid, Eli Lilly deal

    Eli Lilly will acquire migraine company CoLucid for $46.50 per share in cash, or about $960 million. The price is a 33% premium to CoLucid's close of $34.90 on Jan. 17, before the deal was announced. The companies …

    Published on 1/23/2017
  • Columbia University, Lin Bioscience deal

    The university granted Lin Bioscience exclusive, worldwide rights to preclinical candidate LBS-008 and related IP. Lin expects to move the retinol binding protein 4 plasma (RBP4) inhibitor into Phase I testing this year…

    Published on 1/23/2017
  • Derma, Integra deal

    Medical device company Integra will acquire Derma Sciences for $7 per share in a cash deal Derma says values the company at about $204 million. The price is a 40% premium to Dermas close of $5 on Jan. 10, before the …

    Published on 1/23/2017
  • Duke, Enzyvant deal

    The university granted Enzyvant exclusive, worldwide development rights to RVT-802, for which the company plans to submit a BLA to FDA next year to treat complete DiGeorge syndrome. RVT-802 is cultured, partially T cell…

    Published on 1/23/2017
  • Forward, Biogen deal

    Forward will receive $1.25 billion from Biogen as part of a licensing and settlement agreement related to the companies' patent dispute. Biogen said the deal will "clarify and strengthen" its IP protection for multiple …

    Published on 1/23/2017
  • GenVec, Washington University deal

    GenVec said it received an exclusive option from the university for IP and technology related to gene editing and pulmonary endothelial cell targeting technology. GenVec said it will initially combine the technology …

    Published on 1/23/2017
  • Heat, Shattuck deal

    Heat granted newco Shattuck an exclusive license to Heat technology, which Shattuck will use to develop its agonist redirected checkpoint (ARC) platform technology. The technology blocks checkpoint molecules and …

    Published on 1/23/2017
  • MD Anderson, Deerfield Management deal

    MD Anderson and Deerfield Management formed newco Vescor LLC (Houston, Texas) to discover and develop autophagy-targeted cancer treatments. The company will be advised by scientific co-founders Eileen White of Rutgers …

    Published on 1/23/2017
  • Merus, IRB deal

    Merus and the research center partnered to discover and develop bispecific antibodies against undisclosed targets. Merus will fund the research and provide its Biclonics platform. IRB will provide its cell and animal …

    Published on 1/23/2017
  • Nanomerics, Iacta deal

    Nanomerics granted Iacta exclusive, North American rights to develop and commercialize NM133. The nano-enabled form of cyclosporine A delivered using Nanometrics Molecular Envelope Technology is in preclinical testing …

    Published on 1/23/2017
  • NantWorks, Benitec deal

    In December, NantWorks granted Benitec an exclusive, worldwide development sublicense to an undisclosed gene silencing candidate against EGFR to treat head and neck squamous cell cancer (HNSCC). NantWorks is eligible …

    Published on 1/23/2017
  • Novan, Sato deal

    Novan granted Sato exclusive rights to develop and commercialize SB204 and "related dosage forms" in Japan to treat acne. Novan will receive 1.3 billion ($11 million) up front and is eligible for up to 2.8 billion ($24.…

    Published on 1/23/2017
  • Ovid, Takeda deal

    Takeda and Ovid partnered to develop Takeda's TAK-935 in a 50/50 cost- and profit-sharing deal. Takeda received equity in Ovid and is eligible for undisclosed milestones. Ovid will lead development and commercialization…

    Published on 1/23/2017
  • Palatin, AMAG deal

    Palatin granted AMAG exclusive, North American rights to develop and commercialize Rekynda bremelanotide. Palatin will receive $60 million up front and is eligible for up to $80 million in regulatory milestones and up …

    Published on 1/23/2017
  • PharmAthene, Altimmune deal

    PharmAthene and Altimmune will merge into a publicly traded immunotherapeutics company based in Gaithersburg. The newco will retain Altimmunes name and trade on NYSE MKT under the ticker ALT. Altimmune shareholders will…

    Published on 1/23/2017
  • Promethera, LifeLiver deal

    Promethera granted LifeLiver rights to cell therapies HepaStem and H2Stem to treat liver diseases in South Korea. The companies will jointly develop the products to treat non-alcoholic steatohepatitis (NASH) and acute-…

    Published on 1/23/2017
  • Singulex, Qiagen deal

    Singulex and Qiagen partnered to develop companion diagnostics. The partnership will focus on cardiac disease, cancer and inflammation. Singulex will provide its Single Molecule Counting (SMC) diagnostic technology for …

    Published on 1/23/2017
  • Stanford, Aduro deal

    Aduro received an exclusive license to neoantigen identification technology from Stanford. Aduro plans to use the technology to engineer personalized Listeria-based immunotherapies encoding multiple neoantigens, with a …

    Published on 1/23/2017
  • Sumitomo, Sharp Edge deal

    Sumitomo granted Sharp Edge access to the pharma's compound library, which Sharp will use to discover small molecules to treat neurodegenerative disorders. Sharp Edge will use its Fluorogenic Activating Modules …

    Published on 1/23/2017
  • TyrNovo, Kitov deal

    Kitov acquired 56% of TyrNovo for $2 million in cash and $1.8 million in stock. TyrNovos NT219, a small molecule inhibitor of insulin receptor substrate 1 (IRS1), IRS2 and signal transducer and activator of …

    Published on 1/23/2017
  • Viriom, NICHD deal

    Viriom and NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) partnered to improve the antiviral efficacy of undisclosed Viriom compounds to treat Zika, RSV, HCV, HBV, HIV and …

    Published on 1/23/2017

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993